BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 28122247)

  • 1. Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.
    Kremer JC; Prudner BC; Lange SES; Bean GR; Schultze MB; Brashears CB; Radyk MD; Redlich N; Tzeng SC; Kami K; Shelton L; Li A; Morgan Z; Bomalaski JS; Tsukamoto T; McConathy J; Michel LS; Held JM; Van Tine BA
    Cell Rep; 2017 Jan; 18(4):991-1004. PubMed ID: 28122247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
    Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
    Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic arginine starvation in ASS1-deficient cancers inhibits the Warburg effect.
    Kremer JC; Van Tine BA
    Mol Cell Oncol; 2017; 4(3):e1295131. PubMed ID: 28616574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy.
    Long Y; Tsai WB; Wang D; Hawke DH; Savaraj N; Feun LG; Hung MC; Chen HH; Kuo MT
    Cancer Lett; 2017 Mar; 388():54-63. PubMed ID: 27913198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
    Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
    Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASS1 inhibits triple-negative breast cancer by regulating PHGDH stability and de novo serine synthesis.
    Luo W; Zou Z; Nie Y; Luo J; Ming Z; Hu X; Luo T; Ouyang M; Liu M; Tang H; Xie Y; Peng K; Chen L; Zhou J; Luo Z
    Cell Death Dis; 2024 May; 15(5):319. PubMed ID: 38710705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming.
    Brashears CB; Barlin M; Ehrhardt WR; Rathore R; Schultze M; Tzeng SC; Van Tine BA; Held JM
    Cell Death Dis; 2020 Aug; 11(8):662. PubMed ID: 32814773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
    Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
    Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment.
    Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA
    Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino Acid Uptake Measured by [
    Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
    Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
    [No Abstract]   [Full Text] [Related]  

  • 12. Oncogenic Kaposi's Sarcoma-Associated Herpesvirus Upregulates Argininosuccinate Synthase 1, a Rate-Limiting Enzyme of the Citrulline-Nitric Oxide Cycle, To Activate the STAT3 Pathway and Promote Growth Transformation.
    Li T; Zhu Y; Cheng F; Lu C; Jung JU; Gao SJ
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30463977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
    Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
    Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.
    Kim Y; Kobayashi E; Kubota D; Suehara Y; Mukaihara K; Akaike K; Ito A; Kaneko K; Chuman H; Kawai A; Kitano S
    Oncotarget; 2016 Oct; 7(43):70832-70844. PubMed ID: 27683125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
    Allen MD; Luong P; Hudson C; Leyton J; Delage B; Ghazaly E; Cutts R; Yuan M; Syed N; Lo Nigro C; Lattanzio L; Chmielewska-Kassassir M; Tomlinson I; Roylance R; Whitaker HC; Warren AY; Neal D; Frezza C; Beltran L; Jones LJ; Chelala C; Wu BW; Bomalaski JS; Jackson RC; Lu YJ; Crook T; Lemoine NR; Mather S; Foster J; Sosabowski J; Avril N; Li CF; Szlosarek PW
    Cancer Res; 2014 Feb; 74(3):896-907. PubMed ID: 24285724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.
    Locke M; Ghazaly E; Freitas MO; Mitsinga M; Lattanzio L; Lo Nigro C; Nagano A; Wang J; Chelala C; Szlosarek P; Martin SA
    Cell Rep; 2016 Aug; 16(6):1604-1613. PubMed ID: 27452468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
    Bean GR; Kremer JC; Prudner BC; Schenone AD; Yao JC; Schultze MB; Chen DY; Tanas MR; Adkins DR; Bomalaski J; Rubin BP; Michel LS; Van Tine BA
    Cell Death Dis; 2016 Oct; 7(10):e2406. PubMed ID: 27735949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
    Syed N; Langer J; Janczar K; Singh P; Lo Nigro C; Lattanzio L; Coley HM; Hatzimichael E; Bomalaski J; Szlosarek P; Awad M; O'Neil K; Roncaroli F; Crook T
    Cell Death Dis; 2013 Jan; 4(1):e458. PubMed ID: 23328665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
    Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
    Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.